Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 37: 317-326, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kwiterovich, P. O.
Right arrow Articles by Virgil, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwiterovich, P. O., Jr
Right arrow Articles by Virgil, D.

Clinical Chemistry, Vol 37, 317-326, Copyright © 1991 by American Association for Clinical Chemistry

Further insights into the pathophysiology of hyperapobetalipoproteinemia: role of basic proteins I, II, III

PO Kwiterovich Jr, M Motevalli, M Miller, PS Bachorik, SD Kafonek, S Chatterjee, T Beaty and D Virgil
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD.

Hyperapobetalipoproteinemia (hyperapoB), a familial lipoprotein disorder characterized by an increase in small, dense, low-density lipoprotein (LDL) particles, is strongly associated with coronary artery disease. There are two metabolic defects in hyperapoB: an increased synthesis of a very-low-density lipoprotein in liver, resulting in an overproduction of LDL, and a delayed clearance of post- prandial triglyceride and free fatty acids. To date, defects in the apolipoprotein B gene do not appear to explain the hyperapoB phenotype. Defect(s) in the uptake or intracellular metabolism of free fatty acids have been found in cells from hyperapoB patients. Three basic proteins (BPs)--BP I (Mr 14,000, pI 9.10), BP II (Mr 27,500, pI 8.48), and BP III (Mr 55,000, pI 8.73)--were isolated from normal human serum. Compared with normal fibroblasts, cultured hyperapoB fibroblasts incubated with BP I, which appears to be the same protein as acylation- stimulating protein (ASP), showed 50% less stimulation of triglyceride acylation and cholesterol esterification, whereas BP II markedly stimulated cholesteryl ester formation, and BP III caused no difference in response vs normal fibroblasts. However, in cultured normal human monocyte macrophages, BP III, but not BP I or BP II, stimulated cholesteryl esterification two- to threefold. BP I, BP II, and BP III may provide new insights into normal metabolism of lipids, lipoproteins, and free fatty acids and the pathophysiology of hyperapoB.


The following articles in journals at HighWire Press have cited this article:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. O. Kwiterovich Jr and M. Motevalli
Differential Effect of Genistein on the Stimulation of Cholesterol Production by Basic Protein II in Normal and HyperapoB Fibroblasts
Arterioscler. Thromb. Vasc. Biol., January 1, 1998; 18(1): 57 - 64.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Motevalli, P. J. Goldschmidt-Clermont, D. Virgil, and P. O. Kwiterovich Jr.
Abnormal Protein Tyrosine Phosphorylation in Fibroblasts from Hyperapobetalipoproteinemia Subjects
J. Biol. Chem., September 26, 1997; 272(39): 24703 - 24709.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. O. Kwiterovich Jr and M. Motevalli
Inhibition of Protein Tyrosine Kinase Alters the Effect of Serum Basic Protein I on Triacylglycerols and Cholesterol Differently in Normal and HyperapoB Fibroblasts
Arterioscler. Thromb. Vasc. Biol., August 1, 1995; 15(8): 1195 - 1203.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.